← Back to headlines
Goldman Sachs Adjusts Biogen Stock Target Amid Alzheimer's Bet
Goldman Sachs has revised its stock price target for Biogen, citing the pharmaceutical company's significant investment and prospects in Alzheimer's research.
17 May, 20:33 — 17 May, 20:33
Sources
Showing 1 of 1 sources
Related Stories
Amazon's First Customer Receipt Goes Viral, Bezos and Musk React
just now
Central Visayas Experiences Sharpest Cost of Living Increase in Philippines
just now
Misamis Oriental Steel Plant Faces Closure After Raid and Arrests
just now
69 Chinese Nationals Arrested in Raid on Misamis Oriental Steel Plant
just now